Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PI Discretion · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Pegfilgrastim | ACTIVE_COMPARATOR | - |
| Placebo | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PI Discretion | OTHER | PI Discretion |
Inclusion Criteria: - Subjects with histologically confirmed primary peritoneal carcinoma, epithelial ovarian cancer, or tubal carcinoma relapsed after or refractory to 1 or 2 prior regimens of therapy - Measurable or evaluable disease - GOG Performance Status of 0 to 2 - Subjects must be at least 2...
Top 20 of 60 competitors
PI Discretion is an investigational drug being studied for the treatment of ovarian cancer. It is currently in Phase 2 clinical development. The drug has been evaluated in a completed clinical trial involving patients with relapsed or refractory ovarian cancer.
PI Discretion is being developed by Amgen Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AMGN. The company is conducting clinical research to evaluate the drug's safety and efficacy in patients with ovarian cancer.
PI Discretion is in Phase 2 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials. One Phase 2 trial for the drug has been completed.
PI Discretion has been studied in one completed Phase 2 clinical trial with the identifier NCT00113789. The trial, titled "Evaluating Pegfilgrastim and a Multi-Day Topotecan Regimen in Subjects With Relapsed or Refractory Ovarian Cancer," enrolled 21 female patients aged 18 years and older.
No, PI Discretion is not the same as pegfilgrastim. The completed clinical trial NCT00113789 evaluated a multi-day topotecan regimen in combination with pegfilgrastim in patients with ovarian cancer. PI Discretion is the investigational drug being studied in this context.